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Abstract. This study establishes the immune response elicited in guinea pigs after pulmonary and
parenteral immunizations with diphtheria CRM-197 antigen (CrmAg). Several spray-dried powders of
formalin-treated/untreated CrmAg nanoaggregates with L-leucine were delivered to the lungs of guinea
pigs. A control group consisting of alum with adsorbed CrmAg in saline was administered by
intramuscular injection. Animals received three doses of powder vaccines containing 20 or 40 μg of
CrmAg. The serum IgG titers were measured for 16 weeks after the initial immunization; IgA titers were
measured at the time of sacrifice in the broncho-alveolar lavage fluid. Further, toxin neutralization tests
in naïve guinea pigs were performed for a few select serum samples. Histopathology of the lung tissues
was conducted to evaluate inflammation or injury to the lung tissues. While the highest titer of serum IgG
antibody was observed in guinea pigs immunized by the intramuscular route, those animals immunized
with dry powder formulation by the pulmonary route, and without the adjuvant alum, exhibited high IgA
titers. A pulmonary administered dry powder, compared to parenteral immunization, conferred complete
protection in the toxin neutralization test. Mild inflammation was observed in lung tissues of animals
receiving dry powder vaccines by the pulmonary route. Thus, administering novel CrmAg as dry powders
to the lungs may be able to overcome some of the disadvantages observed with the existing diphtheria
vaccine which is administered by the parenteral route. In addition, these powders will have the advantage
of eliciting a high mucosal immune response in the lungs without using traditional adjuvants.
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INTRODUCTION
Diphtheria is a highly contagious upper respiratory tract
disease which can spread from person-to-person by respira-
tory droplets through coughing and sneezing, showing the
importance of mucosal colonization in transmission and
initiation of the disease. It is essential to induce an effective
immune response at these mucosal surfaces, through which
pathogens enter, in addition to stimulating the systemic
immunity. Diphtheria vaccine is administered as a suspension
by the intramuscular (IM) route as part of the mass
immunization program. The use of the IM route is accom-
panied by the problem of contamination and reuse of needles,
a serious concern in many parts of the world where mass
immunizations take place (1). Also, the probability of a local
reaction at the site of injection is pronounced when multiple
vaccines are administered simultaneously (2). The current
diphtheria vaccine consists of four to five doses administered
during infancy, followed by boosters every 10 years for life;
the waning of immunity with age without constant re-
exposure is a concern for the existing vaccine. Over the next
few years, it is anticipated that the use of needles and syringes
will wane in favor of alternatives (3). A non-injectable route
and means of vaccine administration for mass immunization
would likely improve safety and possibly efficacy of diph-
theria vaccination.
The commercial diphtheria vaccine consists of toxin
treated with formalin to mitigate potential toxicity and retain
the immunogenicity of the native form of the antigen (4).
Extrinsic factors such as freezing of the vaccine have been
associated with decreased immune response; freezing disso-
ciates the antigen from the alum, and, thus, interferes with the
vaccine’s immunogenicity. None of the currently licensed
adjuvants intended for use in humans are suitable for mucosal
immunization (5).
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The existing vaccine administered by the parenteral
route usually fails to induce mucosal immunity which is
desirable for reduction in disease dissemination (6). Mucosal
IgA antibody would be advantageous especially in the case of
diphtheria, as the antigen-specific IgA can bind to the
exotoxin released by Corynebacterium diphtheriae, prevent-
ing it from entering and colonizing the mucosal membrane.
Non-invasive vaccination does not require trained medical
personnel, or needles and syringes, and could be an attractive
route of delivery for mass immunization in developing
countries (7). Besides, the development of a heat-stable dry
powder vaccine formulation may help overcome the low
temperature storage and distribution requirements for liquid
vaccine formulations.
Antigen-presenting cells (APCs) such as alveolar macro-
phages and dendritic cells are located in the lungs for antigen
sampling and subsequent presentation to T-cells, making
pulmonary delivery of vaccines desirable (8–10). Increased
vaccine efficacy when delivered by the pulmonary route may
be explained by the prolonged residence time of the antigen
in the alveoli and its subsequent migration to lymphoid
tissues. This contrasts with vaccines administered by other
routes where the antigen is transiently present before it is
cleared from the body.
Given the possibility of an immunotoxicological response
associated with the delivery of traditional adjuvants (alum is
not approved for pulmonary delivery in humans) to the lungs,
pulmonary formulation of vaccines must achieve adjuvancy
by a more specific or localized mechanism, amplifying
antigenicity while avoiding severe side-effects. Dry powder
forms of vaccine for pulmonary delivery have been used in
humans and animal models of disease for prevention of, for
example, tuberculosis, influenza, diphtheria, hepatitis B, and
measles (11–14). One potential alternative approach is
preparation of particles composed of biodegradable polymer,
which can be used to encapsulate the vaccine. The preparation
involves spray-drying poly(lactic-co-glycolic acid) (PLGA)
nanoparticles containing CRM-197 antigen (CrmAg) with
L-leucine to obtain the dry powder formulations. The selection
of PLGA polymer is based on its extensive application in drug
and vaccine delivery to the lung. Incorporation of L-leucine in
the aerosol formulation during spray drying affects the surface
properties of PLGAparticles leading to improvement in powder
flowability and aerosolization properties (15,16). This would in
turn increase the respirable fraction of the total dose. The
resulting nanoparticles containing the antigen need to form
aggregates with a mass median aerodynamic diameter
(MMAD) between 1 and 5 μm for effective delivery to the
lungs, a challenge that can potentially be met using porous
nanoparticle aggregate particle (PNAP) technology as previ-
ously developed (17,18).
The aim of this study was to deliver diphtheria vaccine as
a dry powder for mass vaccination by the pulmonary route
which has the potential to address the following critical issues:
the need to increase efficacy that confers better local mucosal
as well as systemic immunity; the need to demonstrate safety
during administration by reducing the risk of contamination
by sharps and needles; the need to eliminate powder
reconstitution, thus increasing stability during transport,
storage, and administration; and the need to improve cost
effectiveness.
CrmAg is a non-toxic mutant of diphtheria toxin that
cross-reacts immunologically with the toxin. It differs from
diphtheria toxin by a single glycine to glutamic acid change in
position 52 which makes it enzymatically inactive while
retaining protective antibody titers against diphtheria (19); it
binds more strongly to the lipid bilayer of the cell membrane
than the diphtheria toxoid (20). After stabilization with
formalin, CrmAg becomes immunogenic, and is able to
induce protective antibody titers against diphtheria (21).
Several studies have attempted to exploit this advantage by
administering CrmAg to humans and animal models by the
intranasal route for protection against diphtheria (22–26).
However, there are no published clinical or experimental data
for pulmonary vaccination with CrmAg encapsulated in a dry
powder formulation in which a series of immunizations were
performed. Amidi et al. (12) examined the immune response
generated after intra-tracheal administration of diphtheria
toxoid encapsulated in chitosan-based polymers in guinea
pigs. However, their study did not examine the effect of
multiple doses of diphtheria vaccine on the immunity
developed against the toxoid. This approach is important as
new vaccines for diphtheria should induce not only high
antibody titers but also maintain those high levels for
prolonged periods of time.
This study consisted of administering three doses of
CrmAg with PLGA to guinea pigs and examining the
acquired immune response for 16 weeks. The immunogenicity
of pulmonary vaccination of guinea pigs with CrmAg,
delivered in dry powder forms, and determined by the IgG
and IgA responses were addressed. Formulations were
administered at different times and blood was withdrawn at
regular intervals for estimation of serum IgG antibody titers.
Lung IgA antibody titers were evaluated at the time of
sacrifice in the broncho-alveolar lavage fluid (BAL) of the
guinea pigs. Also, toxin-neutralizing antibody titers produced




Goat anti-guinea pig IgG peroxidase conjugate was
purchased from Sigma-Aldrich (St. Louis, MO, USA) and
sheep anti-guinea pig IgA peroxidase conjugate procured
from ICL Inc. for the in vivo enzyme-linked immunosorbent
assay (ELISA). Diphtheria toxin (lot 35119) and antitoxin
were procured from the Office of Vaccines Research and
Review, CBER, FDA. All other chemicals used were of
analytical grade.
Methods
PLGA nanoparticles were prepared by the emulsifica-
tion solvent diffusion method (27) and the double-emulsion
method (28). The particle sizes as measured by photon
correlation spectroscopy were 200±50 nm for all PLGA nano-
particles. The entrapment efficiency of CrmAg within the
PLGA nanoparticles taking into account a theoretical loading
of 1–2% was 87±5% as determined by the bicinchoninic acid
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assay based on the non-entrapped amount of antigen in the
supernatant.
Dry powder formulations with excellent aerosolization
properties for pulmonary delivery were obtained by spray
drying. Aqueous suspensions of CrmAg encapsulated in
PLGA nanoparticles were spray dried (Niro atomizer,
Columbia, MD, USA) with a solution of L-leucine. The ratio
of nanoparticles to L-leucine was kept at 25/75. The inlet and
outlet temperatures of the spray drier were maintained at
95°C and 38°C, respectively. The feed-rate of the solution was
30 mL/min and the air-flow rate 100 kg/h. The different forms
of CrmAg spray dried with L leucine are given in Table I
The volume median diameter of the spray-dried powders
as measured by laser-light diffraction (Sympatec, Germany)
with powder dispersion (Rodos, Sympatec, Germany) was
∼7.0 μm. The MMAD and fine particle fractions determined
by the Andersen eight stage non-viable cascade impactor was
∼5.0 μm and 50%, respectively, based on a particle size cut-
off of <5.8 μm. Tap density was obtained using a Varian tap
density machine by measuring the volume of a known amount
of powder after tapping it for 500 times and was between 0.11
and 0.17 g/cm3 for all the spray-dried powders. Water content
of the powders as measured by Karl Fisher method was less
than 1%.
Scanning electron microscope was used to elucidate the
structures of the PLGA nanoparticles after spray drying with
L-leucine. Hollow- and low-density particles with a rough
inner surface probably due to the presence of intact nano-
particles were obtained when PLGA nanoparticles were
spray dried.
A Western blot analysis was carried out on the antigen
obtained from the spray-dried PLGA particles to ensure that
epitopes present on CrmAg were preserved. Results showed
that antigenic epitopes were preserved during the spray-
drying process. The various dry powder vaccines were stored
in a desiccator at 4°C in-between dosing schedules to prevent
moisture uptake and antigen degradation.
Vaccination and Immunization Schedule
All animal procedures were approved by the University
of North Carolina at Chapel Hill Institutional Animal Care
and Use Committee. Male guinea pigs weighing between 240
and 280 g (Hilltop Laboratory Animals, Inc., Scottdale, PA,
USA) were housed in a 12-h light/12-h dark cycle and
constant temperature of 22°C. A standard diet and water
were supplied ad libitum. Animals were randomly assigned to
seven groups (n=6 each) and immunized with novel CrmAg
formulations administered as dry powders as shown in
Table I. Table I shows the various formulations administered
to guinea pigs, their composition, antigen loading, and route
of administration. Guinea pigs were anesthetized with ket-
amine, xylazine, and acepromazine (3:1:0.5) administered by
the subcutaneous route in the nape of the neck. Dry powder
formulations containing CrmAg were administered to anes-
thetized animals by insufflation. Approximately 10 mg of the
powder, corresponding to 20 or 40 μg of CrmAg (Table I),
were administered with a DP-4 insufflator (Penn Century,
Inc. Philadelphia, PA, USA). Briefly, anesthetized guinea pigs
were placed on their abdomen on a flat surface and the
tracheal opening located by inserting a fiber optic laryngo-
scope (Fiber-Lite system 181-1 Dolan-Jenner Industries, Inc.,
Woburn, MA, USA) into the mouth of the animal. The DP-4
insufflator was loaded with the powder and inserted into the
tracheal opening until the insufflator reached a few milli-
meters from the carina of the lung for proper aerosolization
of the powder. The dry powder was delivered into the lungs
of the guinea pigs by pumping air with a 5-mL disposable
plastic syringe attached to the other end of the insufflator.
The delivered dose was determined by subtracting the weight
of the insufflator after powder administration from that of the
insufflator before administration. The loss of powder adher-
ing inside the insufflator was ≤1 mg; consequently, the dose
+1 mg was loaded to compensate this loss. IM immunization
for the control group was performed in the calf muscle of
anesthetized guinea pigs with the antigens suspended in
sterile phosphate-buffered saline; a volume of 100 μl was
injected. In all cases, the immune responses were followed for
16 weeks after the first immunization.
Measurement of In vivo Antibody Response
ELISA
Blood was collected at regular intervals, from anesthe-
tized animals by the saphenous vein, and serum recovered by
Table I. The Composition of the CRM-197 (CrmAg) Dry Powder Vaccines for Diphtheria, Their Dose, and Route of Administration (n=6






1. Low-dose formalin-treated antigen and
nanoparticle admixture
Formalin-treated CrmAg in a physical mixture
with PLGA nanoparticles
20 Insufflation
2. High-dose formalin-treated antigen and
nanoparticle admixture
Formalin-treated CrmAg in a physical mixture
with PLGA nanoparticles
40 Insufflation










5. Low dose-native antigen in nanoparticles CrmAg encapsulated within PLGA nanoparticles 20 Insufflation
6. High dose-native antigen in nanoparticles CrmAg encapsulated within PLGA nanoparticles 40 Insufflation
7. Low dose-alum with adsorbed antigen Alum with adsorbed Ag 20 Intramuscular
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centrifugation; final bleeding was carried out at week 16 after
the first immunization. After the final bleed, BAL was
performed on the guinea pigs. Sera and lavage fluids were
stored in aliquots at −80°C prior to analysis and frozen
samples thawed only once before analysis.
Anti-CrmAg titer was measured in pooled and individual
serum samples by indirect ELISA. Briefly, 96 well flat-bottom
immuno plates (MaxiSorp, Nalge NUNC International,
Rochester, NY, USA) were coated with CrmAg in 50 μl/well
of coating buffer (50 mM carbonate buffer, pH 9.6) at a
concentration of 2.5 μg/mL at 4°C overnight. The plates were
washed four times with wash buffer (PBS, 0.05% Tween 20
[Sigma, St. Louis, MO, USA]) and blocked to prevent non-
specific binding at 37°C for 2 h with 150 μl/well blocking
buffer (PBS, 0.05% Tween 20, 1% bovine serum albumin).
The blocking buffer was aspirated and the plates washed four
times with wash buffer. Pooled and individual serum samples
diluted in blocking buffer were added to the plates at a
starting dilution of 1:200 and further diluted twofold across
the plates. The plates were incubated at 37°C for 1 h with
50 μl/well of each serum dilution. After aspirating the serum
dilutions and washing four times, the plates were incubated
for another 1 h at 37°C with 50 μl/well of anti-guinea pig IgG
peroxidase conjugate diluted 1/8,000 in blocking buffer. After
aspirating the conjugate and performing the final 4 washes,
the plates were developed with the substrate o-phenylenedi-
amine (OPD, Sigma, Saint Louis, MO, USA) for 30 min at
37°C in the dark. The substrate consisted of one tablet
(10 mg) of OPD, 20 mL of citrate buffer (50 mM, pH 4.9),
and 15 μl of 30% H2O2. The reaction was stopped after
30 min by adding 50 μl/well of 3 M HCL solution to the plates
and optical density measured at 485 nm with 570 nm as the
reference wavelength (Plate CHAMELEON, Multilabel
Detection Platform, Hidex). Relative IgG antibody titers
were determined by comparison to the curve generated with
sera from alum adsorbed with antigen-immunized guinea pigs
and expressed as the reciprocal of the endpoint dilution which
yielded an absorbance value at least three times the back-
ground levels. All samples were analyzed in duplicate.
IgA antibody titers were evaluated in the BAL fluid at
the end of the study (16 weeks post-first immunization) when
the guinea pigs were sacrificed. Guinea pigs were anesthetized
as described earlier and the trachea isolated by a midline
incision. Animals were tracheostomized, and a 14-gauge stain-
less steel catheter was secured with a suture. The animals were
exsanguinated, and the lungs gently perfused three times with
5 mL of saline at room temperature. Recovery volume was
≥80%. The lavage fluid was centrifuged and the saline super-
natant was assayed for IgA antibody titers by ELISA. The
protocol followed was the same as for the evaluation of IgG
titers, except that the anti-guinea pig IgG secondary antibody
was replaced with sheep anti-guinea pig IgA peroxidase
conjugate at a dilution of 1/5,000 in blocking buffer. Non-diluted
BAL samples from individual guinea pigs were added to the
plates and diluted twofold across the plates as before.
Toxin Neutralization Assay
The in vivo toxin-neutralizing test was examined on a
few select serum samples obtained from vaccinated guinea
pigs for specific anti-diphtheria toxin-neutralizing antibodies
as described previously (29). The pooled serum samples were
obtained from guinea pigs vaccinated with low-dose formalin-
treated antigen and nanoparticle admixture, and high-dose
formalin-treated antigen in nanoparticles, dry powders by the
pulmonary route, and the alum adsorbed with antigen group
administered by the IM route. These serum samples were
chosen based on their high IgG antibody titers obtained after
performing ELISA; only three groups were selected due to
the high cost and endpoint sacrifice of the animals in this
assay. The toxin-neutralizing test requires L+ control toxin
dose and is defined as the minimum amount of diphtheria
toxin (0.450 mg/mL) which when mixed with one interna-
tional unit (IU) of diphtheria antitoxin kills a 240–280 g
guinea pig in greater than 48 h and less than 96 h; the L+ dose
of toxin is equivalent to 1.67 limes flocculation and was
verified in four guinea pigs. The diphtheria toxin-specific
antitoxin levels in the serum of vaccinated guinea pigs were
tested at three levels equivalent to 2.0, 1.0, and 0.5 IU/mL;
two naïve guinea pigs were used at each level. Briefly, 2.0 mL
of serum from each of the four immunized guinea pigs was
pooled. The serum was stored at −80°C for later use and was
not thawed more than once.
The preparation of the diphtheria toxin–antitoxin mix-
ture is given in Table II. The concentration of the test dose of
diphtheria toxin was 0.91 mg/mL in saline-G (saline contain-
ing 2% gelatin). The stock diphtheria antitoxin (6 units/mL in
glycerin) was diluted to 1 U/mL in saline-G. The preparation
of the L+ control, negative control and the three values of 0.5,
1.0, and 2.0 IU of antitoxin/mL were tested in naïve guinea
pigs (female) and are reported in Table II. The toxin–
antitoxin mixtures were mixed thoroughly and allowed to
stand at room temperature for 1 h before injecting into guinea
pigs. The mixtures were injected into guinea pigs in the order
Table II. Preparation of the Diphtheria Toxin–Antitoxin Mixture Tested in Naïve Guinea Pigs at Three Levels Equivalent to 2.0, 1.0, and 0.5
International Unit (IU) of Diphtheria Antitoxin/mL solution (n=4 for L+control and n=2 for all other Groups)
Groups Saline Ga (mL) Serum pool (mL) Antitoxin (mL) Toxin (mL) Total volume (mL)
L+Control 3 – 3 3 9
Negative control 6 – 3 – 9
0.5 IUb – 4.5 – 2.25 6.75
1.0 IUb 2.25 2.25 – 2.25 6.75
2.0 IUb 3.37 1.13 – 2.25 6.75
a 2% gelatin in saline
b Pooled serum of vaccinated guinea pigs administered low-dose formalin-treated antigen and nanoparticle admixture, high dose formalin
treated antigen in nanoparticles and alum with adsorbed antigen were tested for neutralizing antibodies
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mixed to prevent degradation due to storage. Of the mixture,
3 mL was injected into each guinea pig subcutaneously.
Animal Response in Toxin-Neutralizing Assay
Guinea pigs were kept alive for 8 days and graded three
times daily according to the degree of diphtheria toxin
symptoms. The test animals (who were administered the
pooled serum obtained from vaccinated guinea pigs along
with the toxin) should survive for more than 96 h in order for
the CrmAg-induced antitoxin to completely neutralize the
toxin.
Lung Histopathological Analysis
A few guinea pigs died during the second and third
dosing in some groups administered dry powder vaccines by
the pulmonary route. The cause of death was investigated to
determine whether it was due to an acute vaccine response or
the degradation/endotoxin contamination of the stored dry
powder vaccine. Naïve guinea pigs (two for each group)
received the dry powder vaccines by the pulmonary route and
were sacrificed after 48 h. Lung tissues were collected in 10%
formalin. Likewise, the lung tissues of guinea pigs that had
died during the second/third dosing of the vaccine were
preserved in formalin. Any inflammatory or microscopic
changes occurring in the lungs following multiple dosing with
the dry powder vaccine were noted. Tissues were embedded
in paraffin, sectioned at 5 μm, mounted on slides, and stained
with H&E. Slides were examined by a board-certified
veterinary pathologist at Charles River laboratories-Pathol-
ogy Associates.
STATISTICAL ANALYSIS
One-way ANOVA was used to compare the data. Post
hoc pair-wise multiple comparisons were conducted using
Bonferonni t test when the differences in the means were
significant (Sigmaplot version 11, Systat Software, Inc., CA,




Various dry powder formulations containing CrmAg
encapsulated in PLGA were administered to guinea pigs by
the pulmonary route and the immune response elicited, based
on the serum IgG and BAL IgA, assessed. As shown in Fig. 1,
an increase in the IgG titers was observed in all of the
immunized groups 15 days after the second immunization
except the high-dose native antigen in nanoparticles group.
The high-dose native antigen in nanoparticle-immunized
animals achieved antibody titers similar to other pulmonary
immunized animals 30 days after the second immunization.
Guinea pigs immunized with alum adsorbed with antigen by
the IM route achieved higher initial antibody titers (30 days
after the first dose) compared to the groups immunized by the
pulmonary route. The high titer values in the alum adsorbed
with antigen group were further boosted after the second
immunization. Surprisingly, the third dose, administered
12 weeks after the first dose, boosted the immunity margin-
ally in all groups including the alum-adsorbed-with-antigen
group (Fig. 1). At the time of sacrifice (16 weeks after the first
immunization), animals treated with alum adsorbed with
antigen (by the IM route) elicited significantly (p<0.001)
higher IgG titers compared to groups receiving dry powder
vaccines by the pulmonary route (Fig. 1). Guinea pigs
receiving various dry powder vaccines by the pulmonary
route raised similar IgG responses, regardless of the different
antigenic formulations.
IgA antibody titers at week 16 in the lungs of guinea pigs
were higher in the groups receiving the novel dry powder
formulations by the pulmonary route compared to those
receiving alum adsorbed with antigen administered by the IM
route (Fig. 2). IgA titers for low-dose native antigen in
nanoparticles and high-dose native antigen in nanoparticle-
immunized guinea pigs were significantly higher (P<0.001
and P<0.003, respectively) than for all of the other immu-
nized groups. Dry powder formulations in which the CrmAg
was treated with formalin did not elicit a substantial IgA
response in the lungs. However, an immunological advantage
is clearly afforded by pulmonary administration of dry
powder vaccines with respect to eliciting mucosal immunity.
Toxin-Neutralizing Assay
The toxin-neutralizing tests were performed for serum
samples obtained from vaccinated guinea pigs. The serum
samples were tested at three levels equivalent to 2.0, 1.0, and
0.5 IU/mL of diphtheria antitoxin. After administering the
Fig. 1. Anti-CRM-197 antigen-specific serum IgG titers in guinea pigs
after three doses of immunization with dry powder formulations
administered by the pulmonary route. Responses are compared to those
determined for guinea pigs administered with CRM-197 antigen-
adsorbed alum by the intramuscular route. Error bars represent the
mean±standard error.Arrows indicate the immunization schedule which
corresponds to 0, 6, and 12 weeks. Antibody titers are expressed as the
reciprocal of the sample dilution corresponding to at least three times the
background level. #NP nanoparticles. Asterisk denotes results are
significantly different than all other treatment groups, P<0.001
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serum-toxin mixture, the guinea pigs were monitored three
times daily and weighed once a day, and given a score for any
diphtheria toxin symptoms (data not shown).
As shown in Fig. 3, naïve guinea pigs injected with high
dose formalin-treated antigen in nanoparticles serum-toxin
mixture survived at all three levels of antitoxin. The low-dose
formalin-treated antigen and nanoparticle-admixture serum
obtained from the pulmonary vaccinated guinea pigs could
not neutralize the toxin at any of the doses examined and the
animals administered with this serum mixture died within
96 h. In the guinea pigs administered the alum-adsorbed-with-
antigen-serum sample, the toxin was completely neutralized
at the 0.5 and 1.0 IU/mL level. A partial neutralization of the
toxin was obtained for the 2.0 IU/mL level as the animals
survived beyond 48 h but not 96 h (Fig. 3).
Histopathology
The deaths of guinea pigs receiving the second and third
immunizations were investigated. Since the guinea pigs in the
study were exposed to three doses of CrmAg encapsulated in
PLGA for 12 weeks, we sought to identify the potential
inflammatory or toxicity reaction occurring in the lungs due
to multiple dosing. Naïve guinea pigs receiving dry powder
vaccines and sacrificed after 48 h had mild acute inflamma-
tion. The inflammation was located in the central portion of
the lungs, particularly around the main airways, and consisted
of a diffuse infiltrate of a small number of neutrophils that
were present within alveolar lumens and the lumens of some
small airways. There were no other signs of toxicity observed
in these lung tissues. Guinea pigs that died after the second
and third doses had mild multifocal chronic inflammation in a
few tissues, with most of the lung tissues showing no
remarkable changes. The chronic inflammation consisted of
areas of the alveoli that were filled with alveolar macro-
phages. In addition, small lymphoid nodules (dense areas)
were present within the foci of the chronic inflammation.
These observations were not specific to any particular group
vaccinated by the pulmonary route (Fig. 4a and b correspond
to low-dose formalin-treated antigen in nanoparticles and
low-dose formalin-treated antigen and nanoparticle admix-
ture administered guinea pigs).
DISCUSSION
Immunization by the pulmonary route in the prophylaxis
and therapy of infectious diseases is still in its early stages
(30). Diphtheria was the first disease in which passive
antibody therapy was shown to be effective. The extracellular
toxin secreted by the bacteria can be neutralized by reacting
with antibodies before the toxin can bind to host cells; the
tertiary structure of the toxin is altered by these antibodies.
Neutralizing antibodies are thus protective responses that mimic
responses to a natural infection. Vaccines based on CrmAg
induce the production of anti-CrmAg antibodies; these anti-
bodies also recognize diphtheria toxin as the CrmAg differs
from the native toxin by only one amino acid (31).
Nanoparticles have been employed in drug and vaccine
delivery because of their ability to enhance absorption and
migration through tissues and cells. Since nanoparticles tend
to agglomerate due to their high surface-to-volume ratio, they
have been incorporated into porous microparticles through
the spray-drying process to form structures that may contain
varying proportions of nanoparticles. Once delivered to the
deep lung, these appropriately sized particles will collapse to
release the nanoparticles in the alveolar region.
In the present study, dry powders intended for vaccine
delivery were prepared based on the PNAP technology (17,18).
In the form of nanoparticles, it was feasible to entrap significant
quantities of CrmAg without damaging the epitopes when
Fig. 2. The last time-point (week 16) CRM-197 antigen-specific
broncho-alveolar lavage IgA antibody titers in guinea pigs after three
doses of immunization with novel dry powder formulations adminis-
trated by the pulmonary routes. Responses are compared to those
determined for guinea pigs administered with CRM-197 antigen-
adsorbed alum by the intramuscular route. Error bars represent the
mean±standard error. Antibody titers are expressed as the reciprocal
of the sample dilution corresponding to at least three times the
background level. ** and * denotes results are significantly different
than all other treatment groups, P<0.001 and P<0.003, respectively.
No last time period antibody titers for the high-dose formalin-treated
antigen and nanoparticle admixture group as all of the guinea pigs in
this group died during the study. #NP nanoparticles
Fig. 3. Toxin-neutralizing test performed on the serum samples of
vaccinated guinea pigs at three levels equivalent to 2.0, 1.0, and 0.5
international unit (IU) of diphtheria antitoxin/mL. Nabs-neutralizing
antibodies; L-AlumAg low-dose alum with adsorbed antigen, H-
FAgN high-dose formalin-treated antigen in nanoparticles, L-FAgNA
low-dose formalin-treated antigen and nanoparticle admixture
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analyzed byWestern blot. CrmAgwas incorporated into various
spray-dried formulations containing nanoparticles that influ-
enced the aerosol particle properties by increasing their geo-
metric diameter and lowering their density while maintaining an
aerodynamic diameter that allows for deposition in the deep
lung (MMAD between 1 and 5 μm). These nanoparticles
contained the CrmAg either within their structures or as free
antigen in a physical mixture, and thus helped maintain its
stability. The volume median diameter, density, and MMAD of
the dry powders were appropriate for deposition in the deep
lung.
The guinea pig model was used in this study because it is
known to correlate with humans with respect to the toxin-
neutralizing test in vitro and in vivo. Guinea pigs are used for
potency evaluation of novel diphtheria vaccines because,
unlike mice, they are responsive to the lethal effects of
diphtheria toxin and show protection against challenge after
immunization (32). Guinea pigs are also the animal of choice
for evaluating adjuvant formulations as mice have previously
shown inconsistent responses to adjuvants (33). However, the
scarcity of immunological reagents for guinea pigs and the
high cost of maintaining them have acted as impediments to
their widespread use in new vaccine studies.
Conventional diphtheria vaccines consists of ‘inactivated
toxin’ administered as a series of four to five doses, and then
as a single dose every 10 years to boost the waning antibody
titers. The initial design for our study had a series of three
doses administered 12 weeks apart. However, Fig. 1 illustrates
that two doses are sufficient to provide and maintain high IgG
titers in the systemic circulation for 45 days after the second
dose (prior to the last immunization) in guinea pigs. After
two immunizations, the antibody responses reached a plateau
and only increased slightly after the third dose in all of the
immunized animals irrespective of the route of administration
(Fig. 1); the last immunization may have helped to sustain the
titer levels. Since the guinea pigs were sacrificed 4 weeks after
the last dose (16 weeks after the first immunization), we could
not anticipate the level of the antibody titers beyond this
point. Future studies should consider the long-term effect of
multiple immunization regimens on the antibody titers.
The significantly high serum IgG response elicited by the
alum-adsorbed-with-antigen group (administered by the IM
route) compared to dry powder vaccines administered by the
pulmonary route may have been due to the presence of alum
(Fig. 1); it has been shown that antigen delivered with alum in
parenteral vaccines, rather than in a mucosal vaccine, form
persistent areas of high local antigen concentration at the
injection site which may allow the host immune system to
interact for an extended period of time with the antigen (34).
However, unlike serum IgG titers, IgA antibodies
generated in the lungs at week 16 after the first immunization
were higher for guinea pigs receiving the dry powder vaccines
by the pulmonary route compared to those subjected to IM
delivery (Fig. 2). Low-dose native antigen in nanoparticles
and high-dose native antigen in nanoparticles vaccines
administered to guinea pigs by the pulmonary route elicited
a significantly higher IgA response than the alum-adsorbed-
with-antigen group administered by the IM route, suggesting
that alum-containing parenteral vaccines are poor generators
of mucosal immune response (35). Indeed, guinea pigs
receiving alum adsorbed with antigen by the IM route, which
elicited a high systemic IgG response, had low IgA titers in
the BAL fluid. Thus, the administration of parenteral
vaccines containing alum has the propensity to elicit high
IgG titers in the serum but may not be sufficient to evoke an
IgA mucosal response in the lungs which is desirable to
prevent dissemination of diphtheria infection from the upper
respiratory tract. We did not examine the IgG titers in the
BAL fluid though they are evoked significantly in response to
infection or vaccination. The IgG in BAL fluid approximates
the serum titer, with the majority of the (BAL) IgG coming
from transudation from the plasma compartment (36).
Interestingly, the low-dose native antigen in nanopar-
ticles and high-dose native antigen in nanoparticles groups,
that elicited significantly higher IgA titers compared to other
immunized groups (Fig. 2) including the IM-administered
alum-adsorbed-with antigen group, did not contain formalin-
treated CrmAg. Formalinization of CrmAg of diphtheria
toxin may sometimes contribute to alteration of protein
epitopes leading to decrease in antigenicity and immunoge-
nicity (32), although there have been reports where potency
has increased after formalin treatment (37). However, this
Fig. 4. Microscopic evaluation of the lung tissue of guinea pigs after
administering a low-dose formalin-treated antigen in nanoparticles
and b low-dose formalin-treated antigen and nanoparticle admixture.
Both magnifications were at 4×. Arrows show dense regions consist-
ing of lymphoid nodules
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does not explain the formalin-treated CrmAg eliciting
equivalent IgG titers to those of untreated antigen groups in
the serum of animals in our study. In other studies, native
CrmAg has been shown to be less immunogenic in guinea
pigs and formalin-treated antigen has led to improvement in
its immunogenicity by stabilization of the molecule (21,32).
However, these studies did not examine the effect of formalin
treatment of the antigen on the lung IgA titers which is critical to
give protection in the respiratory tract; our study showed
significantly lower IgA titers in the BAL fluid (p<0.001) and
similar IgG titers in serum for antigens treated with formalin.
Low IgA titers in animals administered formalin-treatedCrmAg
may have been due to toxicity of formalin to APCs in the lung.
Further studies are required to examine the effect of formalin-
treated antigen on the mechanism of IgA and IgG antibody
production, and are beyond the scope of this work.
The antitoxin titers in vaccinated animals against diph-
theria can be estimated by in vitro methods such as Vero cell
method and D ELISA, and by the in vivo toxin-neutralizing
assay. The ELISA method does not distinguish between non-
neutralizing and neutralizing antibodies whereas the toxin-
neutralizing assay measures only the protective antibodies
(38). In our study, the toxin-neutralizing test in naïve guinea
pigs showed that the serum from the pulmonary vaccinated
high-dose formalin-treated antigen in nanoparticles group
afforded protection at all concentrations of antitoxin used
(0.5, 1.0 and 2.0 IU/mL; Fig. 3; >0.01 IU/mL is protective in
man according to the WHO) (39). On the contrary, the low-
dose formalin-treated antigen and nanoparticle admixture
group failed to provide protection at any level of antitoxin
tested. Interestingly, the alum-adsorbed-with-antigen group
that had elicited significantly higher IgG levels compared to
other immunized groups was able to neutralize the toxin only
at the 0.5 and 1.0 IU level of antitoxin/mL. This demonstrates
that the high IgG titers in the serum do not necessarily
correspond to high titers of protective neutralizing antibodies
(38).
The potential inflammatory reaction occurring in the
lungs after multiple dosing of the dry powder vaccine was
investigated. Mild acute inflammation was observed in guinea
pigs administered a single dose of vaccine. Animals exposed
to multiple doses of dry powder had multifocal chronic
inflammation in a few lung tissues. Presence of lymphoid
nodules within the foci confirms the presence of a chronic
inflammatory response (Fig. 4 a and b). There remains a
possibility that some of the deaths observed after multiple
vaccination may have been due to the presence of formalin in
the dry powders.
Intranasal immunization with CrmAg has been shown to
induce systemic antibody responses comparable to, or greater
than, those achieved with parenteral immunization (25).
Amidi et al. showed that diphtheria toxoid encapsulated in
chitosan was able to elicit high IgA antibody titers in guinea
pigs at the respiratory epithelium and mucosal sites (12). The
lungs, therefore, may prove a promising alternative route for
administration of novel dry powder diphtheria vaccines.
The requirement for adjuvancy was indicated by the
absence of significant IgG titers in the serum of guinea pigs
immunized by the pulmonary route with the dry powders not
containing any adjuvant. Interestingly, IgA titers in the lungs
were higher when these powder formulations were adminis-
tered by the pulmonary route compared to CrmAg adminis-
tered by the IM route along with alum (Fig. 2). Currently,
alum is the only approved adjuvant for human vaccines
including multiple diphtheria vaccine which is administered
by the parenteral route.
The mechanism by which serum antibody titers are
developed after delivering antigens to the lungs is not clearly
known, but may be due to the presence of APCs and their
proximity to mediastinal lymph nodes. Other factors may also
be involved and undoubtedly, further studies are required to
explore the relevant mechanisms. Future studies should also
look for a correlation between systemic IgG and mucosal IgA
titers, and the protective effect of these antibodies after
pulmonary vaccination.
CONCLUDING REMARKS
The studies described here demonstrate that pulmonary
immunization with dry powder vaccines against diphtheria
may lead to a high mucosal immune response in the
respiratory tract and sufficient neutralizing antibodies in the
systemic circulation to provide protection against this disease.
It may be concluded that the lungs could be a suitable route
of administration for novel dry powder vaccines that may
offer not only clinical advantages but also the pharmaceutical
advantages of absence of needles in a mass immunization
program and absence of a cold chain for delivery globally.
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